

## HALF-YEAR INCOME STATEMENT - 2007 to 2009

	2009*		2008		2007	
<i>in million euros</i>	H1	H2	H1	H2	H1	H2
<b>SALES</b>	3,472	4,027	4,848	3,829	4,944	4,611
Total other revenues					62	72
<b>TOTAL OPERATING REVENUES</b>					<b>5,006</b>	<b>4,683</b>
<b>GROSS MARGIN</b>	<b>453</b>	<b>685</b>	<b>797</b>	<b>530</b>	<b>771</b>	<b>726</b>
<i>in % of sales</i>	<b>13.0%</b>	<b>17.0%</b>	<b>16.4%</b>	<b>13.8%</b>	<b>15.6%</b>	<b>15.7%</b>
R&D expenses	-234	-239	-276	-225	-341	-327
<i>in % of sales</i>	-6.7%	5.9%	-5.7%	-5.9%	-6.8%	-7.0%
SG&A expenses	-270	-262	-318	-278	-315	-302
<i>in % of sales</i>	-7.8%	-6.5%	-6.5%	-7.3%	-6.3%	-6.4%
<b>OPERATING MARGIN</b>	<b>-51</b>	<b>184</b>	<b>203</b>	<b>27</b>	<b>177</b>	<b>169</b>
<i>in % of sales</i>	<b>-1.5%</b>	<b>4.6%</b>	<b>4.2%</b>	<b>0.7%</b>	3.5%	3.6%
Other Income & Expenses	-37	-12	-21	-261	-10	-17
<i>in % of sales</i>	-1.1%	-0.3%	-0.4%	-6.8%	-0.2%	-0.4%
<b>OPERATING INCOME</b>	<b>-88</b>	<b>172</b>	<b>182</b>	<b>-234</b>	<b>167</b>	<b>152</b>
<i>in % of sales</i>	<b>-2.5%</b>	<b>4.3%</b>	<b>3.8%</b>	<b>-6.1%</b>	3.3%	3.2%
Interest Expenses net	-21	-39	-22	-23	-25	-26
Other Financial Expenses	-37	-20	-6	-53	-20	-26
Equity in net earnings of Associated Companies	-40	6	7	2	5	3
<b>INCOME BEFORE TAXES</b>	<b>-186</b>	<b>119</b>	<b>161</b>	<b>-308</b>	<b>127</b>	<b>103</b>
<i>in % of sales</i>	<b>-5.4%</b>	<b>2.9%</b>	<b>3.3%</b>	<b>-8.0%</b>	2.5%	2.2%
Effective tax rate	17.8%	-46.9%	-36.4%	-1.6%	-38.5%	-36.0%
<b>NET INCOME FROM CONSOLIDATED COMPANIES</b>	<b>-212</b>	<b>66</b>	<b>105</b>	<b>-303</b>	<b>80</b>	<b>67</b>
Non strategic activities	1	-1	-1	0	-4	-55
<b>NET INCOME FOR THE PERIOD</b>	<b>-211</b>	<b>65</b>	<b>104</b>	<b>-303</b>	<b>76</b>	<b>12</b>
Minority interest	-2	-6	0	-4	-5	-2
<b>NET INCOME</b>	<b>-213</b>	<b>60</b>	<b>104</b>	<b>-307</b>	<b>71</b>	<b>10</b>
<i>in % of sales</i>	<b>-6.1%</b>	<b>1.5%</b>	<b>2.1%</b>	<b>-8.0%</b>	1.4%	0.2%

\* As of January 1, 2009, the presentation of the financial statements has been modified, with other operating revenues now being mainly reclassified as deductible research and development expenses.